nodes	percent_of_prediction	percent_of_DWPC	metapath
Triamterene—Irreversible renal failure—Gemcitabine—lung cancer	0.0458	0.0989	CcSEcCtD
Triamterene—Irreversible renal failure—Cisplatin—lung cancer	0.0427	0.0922	CcSEcCtD
Triamterene—SCNN1B—mammary gland—lung cancer	0.0349	0.0857	CbGeAlD
Triamterene—SCNN1A—mammary gland—lung cancer	0.0322	0.0792	CbGeAlD
Triamterene—SCNN1G—respiratory system—lung cancer	0.0275	0.0676	CbGeAlD
Triamterene—SCNN1D—respiratory system—lung cancer	0.0275	0.0676	CbGeAlD
Triamterene—SCNN1B—respiratory system—lung cancer	0.0233	0.0571	CbGeAlD
Triamterene—SCNN1D—epithelium—lung cancer	0.023	0.0565	CbGeAlD
Triamterene—SCNN1G—bronchus—lung cancer	0.0226	0.0557	CbGeAlD
Triamterene—SCNN1A—respiratory system—lung cancer	0.0215	0.0528	CbGeAlD
Triamterene—SCNN1B—epithelium—lung cancer	0.0194	0.0478	CbGeAlD
Triamterene—SCNN1B—bronchus—lung cancer	0.0191	0.047	CbGeAlD
Triamterene—SCNN1A—epithelium—lung cancer	0.018	0.0441	CbGeAlD
Triamterene—SCNN1A—bronchus—lung cancer	0.0177	0.0434	CbGeAlD
Triamterene—SCNN1B—trachea—lung cancer	0.0172	0.0422	CbGeAlD
Triamterene—Renal failure chronic—Gemcitabine—lung cancer	0.016	0.0346	CcSEcCtD
Triamterene—SCNN1A—trachea—lung cancer	0.0159	0.039	CbGeAlD
Triamterene—Renal failure chronic—Cisplatin—lung cancer	0.015	0.0323	CcSEcCtD
Triamterene—SCNN1G—lung—lung cancer	0.0146	0.0359	CbGeAlD
Triamterene—SCNN1D—lung—lung cancer	0.0146	0.0359	CbGeAlD
Triamterene—SCNN1B—lung—lung cancer	0.0123	0.0303	CbGeAlD
Triamterene—SCNN1A—lung—lung cancer	0.0114	0.028	CbGeAlD
Triamterene—SCNN1D—lymph node—lung cancer	0.00999	0.0246	CbGeAlD
Triamterene—Anaemia megaloblastic—Methotrexate—lung cancer	0.00938	0.0202	CcSEcCtD
Triamterene—SCNN1B—lymph node—lung cancer	0.00844	0.0208	CbGeAlD
Triamterene—Renal failure acute—Pemetrexed—lung cancer	0.00824	0.0178	CcSEcCtD
Triamterene—SCNN1A—lymph node—lung cancer	0.0078	0.0192	CbGeAlD
Triamterene—Hypokalaemia—Crizotinib—lung cancer	0.00757	0.0163	CcSEcCtD
Triamterene—Hypokalaemia—Gefitinib—lung cancer	0.00688	0.0148	CcSEcCtD
Triamterene—CYP1A2—respiratory system—lung cancer	0.00516	0.0127	CbGeAlD
Triamterene—Renal failure acute—Erlotinib—lung cancer	0.00489	0.0106	CcSEcCtD
Triamterene—Azotaemia—Methotrexate—lung cancer	0.00415	0.00895	CcSEcCtD
Triamterene—Hypokalaemia—Erlotinib—lung cancer	0.00411	0.00886	CcSEcCtD
Triamterene—Blood urea increased—Gemcitabine—lung cancer	0.00408	0.0088	CcSEcCtD
Triamterene—Hyperkalaemia—Cisplatin—lung cancer	0.00396	0.00854	CcSEcCtD
Triamterene—Dry mouth—Gefitinib—lung cancer	0.00379	0.00817	CcSEcCtD
Triamterene—Anaphylactic shock—Pemetrexed—lung cancer	0.00374	0.00806	CcSEcCtD
Triamterene—Thrombocytopenia—Pemetrexed—lung cancer	0.00366	0.00789	CcSEcCtD
Triamterene—Thrombocytopenia—Gefitinib—lung cancer	0.00364	0.00784	CcSEcCtD
Triamterene—Fatigue—Crizotinib—lung cancer	0.00353	0.0076	CcSEcCtD
Triamterene—Renal failure acute—Irinotecan—lung cancer	0.00349	0.00752	CcSEcCtD
Triamterene—Fatigue—Pemetrexed—lung cancer	0.00322	0.00695	CcSEcCtD
Triamterene—Fatigue—Gefitinib—lung cancer	0.0032	0.0069	CcSEcCtD
Triamterene—Renal failure acute—Cisplatin—lung cancer	0.00317	0.00683	CcSEcCtD
Triamterene—SCNN1D—Transmembrane transport of small molecules—SLC34A2—lung cancer	0.00308	0.0243	CbGpPWpGaD
Triamterene—Thrombocytopenia—Teniposide—lung cancer	0.00296	0.00639	CcSEcCtD
Triamterene—Asthenia—Crizotinib—lung cancer	0.00293	0.00633	CcSEcCtD
Triamterene—Hypokalaemia—Irinotecan—lung cancer	0.00293	0.00632	CcSEcCtD
Triamterene—Hypokalaemia—Gemcitabine—lung cancer	0.00285	0.00616	CcSEcCtD
Triamterene—Renal failure acute—Paclitaxel—lung cancer	0.00284	0.00614	CcSEcCtD
Triamterene—Diarrhoea—Crizotinib—lung cancer	0.0028	0.00603	CcSEcCtD
Triamterene—Hypersensitivity—Pemetrexed—lung cancer	0.00275	0.00594	CcSEcCtD
Triamterene—CYP1A2—lung—lung cancer	0.00274	0.00673	CbGeAlD
Triamterene—Hypersensitivity—Gefitinib—lung cancer	0.00274	0.0059	CcSEcCtD
Triamterene—Dizziness—Crizotinib—lung cancer	0.0027	0.00583	CcSEcCtD
Triamterene—Asthenia—Pemetrexed—lung cancer	0.00268	0.00578	CcSEcCtD
Triamterene—Asthenia—Gefitinib—lung cancer	0.00266	0.00575	CcSEcCtD
Triamterene—Hypokalaemia—Cisplatin—lung cancer	0.00266	0.00574	CcSEcCtD
Triamterene—Vomiting—Crizotinib—lung cancer	0.0026	0.00561	CcSEcCtD
Triamterene—Rash—Crizotinib—lung cancer	0.00258	0.00556	CcSEcCtD
Triamterene—Dermatitis—Crizotinib—lung cancer	0.00258	0.00556	CcSEcCtD
Triamterene—Diarrhoea—Pemetrexed—lung cancer	0.00256	0.00551	CcSEcCtD
Triamterene—Diarrhoea—Gefitinib—lung cancer	0.00254	0.00548	CcSEcCtD
Triamterene—Lamotrigine—ABCB1—lung cancer	0.00252	1	CrCbGaD
Triamterene—Dizziness—Pemetrexed—lung cancer	0.00247	0.00533	CcSEcCtD
Triamterene—Nausea—Crizotinib—lung cancer	0.00243	0.00524	CcSEcCtD
Triamterene—Jaundice—Irinotecan—lung cancer	0.00242	0.00522	CcSEcCtD
Triamterene—Hypokalaemia—Paclitaxel—lung cancer	0.00239	0.00516	CcSEcCtD
Triamterene—Vomiting—Pemetrexed—lung cancer	0.00238	0.00512	CcSEcCtD
Triamterene—Vomiting—Gefitinib—lung cancer	0.00236	0.00509	CcSEcCtD
Triamterene—Rash—Pemetrexed—lung cancer	0.00236	0.00508	CcSEcCtD
Triamterene—Dermatitis—Pemetrexed—lung cancer	0.00235	0.00508	CcSEcCtD
Triamterene—Rash—Gefitinib—lung cancer	0.00234	0.00505	CcSEcCtD
Triamterene—Dermatitis—Gefitinib—lung cancer	0.00234	0.00504	CcSEcCtD
Triamterene—SCNN1G—Transmembrane transport of small molecules—SLC22A18—lung cancer	0.00233	0.0184	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—SLC22A18—lung cancer	0.00233	0.0184	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—SLC22A18—lung cancer	0.00233	0.0184	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—SLC22A18—lung cancer	0.00233	0.0184	CbGpPWpGaD
Triamterene—Thrombocytopenia—Vinblastine—lung cancer	0.00226	0.00488	CcSEcCtD
Triamterene—Anaphylactic shock—Topotecan—lung cancer	0.00224	0.00484	CcSEcCtD
Triamterene—Hypersensitivity—Teniposide—lung cancer	0.00223	0.00481	CcSEcCtD
Triamterene—Nausea—Pemetrexed—lung cancer	0.00222	0.00479	CcSEcCtD
Triamterene—Nausea—Gefitinib—lung cancer	0.00221	0.00476	CcSEcCtD
Triamterene—Thrombocytopenia—Topotecan—lung cancer	0.0022	0.00474	CcSEcCtD
Triamterene—Thrombocytopenia—Erlotinib—lung cancer	0.00217	0.00469	CcSEcCtD
Triamterene—Asthenia—Teniposide—lung cancer	0.00217	0.00468	CcSEcCtD
Triamterene—Photosensitivity reaction—Paclitaxel—lung cancer	0.00207	0.00447	CcSEcCtD
Triamterene—Diarrhoea—Teniposide—lung cancer	0.00207	0.00447	CcSEcCtD
Triamterene—Jaundice—Etoposide—lung cancer	0.00201	0.00434	CcSEcCtD
Triamterene—Fatigue—Topotecan—lung cancer	0.00193	0.00417	CcSEcCtD
Triamterene—Vomiting—Teniposide—lung cancer	0.00192	0.00415	CcSEcCtD
Triamterene—Anaphylactic shock—Vinorelbine—lung cancer	0.00192	0.00414	CcSEcCtD
Triamterene—Fatigue—Erlotinib—lung cancer	0.00191	0.00413	CcSEcCtD
Triamterene—Rash—Teniposide—lung cancer	0.00191	0.00412	CcSEcCtD
Triamterene—Dermatitis—Teniposide—lung cancer	0.00191	0.00411	CcSEcCtD
Triamterene—Headache—Teniposide—lung cancer	0.0019	0.00409	CcSEcCtD
Triamterene—Hyperkalaemia—Doxorubicin—lung cancer	0.00188	0.00406	CcSEcCtD
Triamterene—Thrombocytopenia—Vinorelbine—lung cancer	0.00188	0.00405	CcSEcCtD
Triamterene—Photosensitivity—Methotrexate—lung cancer	0.00183	0.00394	CcSEcCtD
Triamterene—Blood urea increased—Doxorubicin—lung cancer	0.00181	0.0039	CcSEcCtD
Triamterene—Nausea—Teniposide—lung cancer	0.0018	0.00388	CcSEcCtD
Triamterene—SCNN1D—Stimuli-sensing channels—RAF1—lung cancer	0.00177	0.014	CbGpPWpGaD
Triamterene—SCNN1A—Stimuli-sensing channels—RAF1—lung cancer	0.00177	0.014	CbGpPWpGaD
Triamterene—SCNN1G—Stimuli-sensing channels—RAF1—lung cancer	0.00177	0.014	CbGpPWpGaD
Triamterene—SCNN1B—Stimuli-sensing channels—RAF1—lung cancer	0.00177	0.014	CbGpPWpGaD
Triamterene—CYP1A2—Xenobiotics—CYP2A7—lung cancer	0.00176	0.0139	CbGpPWpGaD
Triamterene—Renal failure acute—Methotrexate—lung cancer	0.00174	0.00375	CcSEcCtD
Triamterene—Hypersensitivity—Vinblastine—lung cancer	0.0017	0.00367	CcSEcCtD
Triamterene—Jaundice—Docetaxel—lung cancer	0.00167	0.00361	CcSEcCtD
Triamterene—Asthenia—Vinblastine—lung cancer	0.00166	0.00357	CcSEcCtD
Triamterene—Fatigue—Vinorelbine—lung cancer	0.00165	0.00357	CcSEcCtD
Triamterene—Hypersensitivity—Topotecan—lung cancer	0.00165	0.00356	CcSEcCtD
Triamterene—Asthenia—Topotecan—lung cancer	0.00161	0.00347	CcSEcCtD
Triamterene—Asthenia—Erlotinib—lung cancer	0.00159	0.00343	CcSEcCtD
Triamterene—Anaphylactic shock—Irinotecan—lung cancer	0.00158	0.00341	CcSEcCtD
Triamterene—Photosensitivity—Doxorubicin—lung cancer	0.00158	0.00341	CcSEcCtD
Triamterene—Diarrhoea—Vinblastine—lung cancer	0.00158	0.00341	CcSEcCtD
Triamterene—Thrombocytopenia—Irinotecan—lung cancer	0.00155	0.00334	CcSEcCtD
Triamterene—Anaphylactic shock—Gemcitabine—lung cancer	0.00154	0.00333	CcSEcCtD
Triamterene—Diarrhoea—Topotecan—lung cancer	0.00154	0.00331	CcSEcCtD
Triamterene—Dizziness—Vinblastine—lung cancer	0.00153	0.00329	CcSEcCtD
Triamterene—CYP1A2—Aflatoxin B1 metabolism—GSTM1—lung cancer	0.00152	0.012	CbGpPWpGaD
Triamterene—Diarrhoea—Erlotinib—lung cancer	0.00152	0.00328	CcSEcCtD
Triamterene—Thrombocytopenia—Gemcitabine—lung cancer	0.00151	0.00326	CcSEcCtD
Triamterene—Renal failure acute—Doxorubicin—lung cancer	0.0015	0.00325	CcSEcCtD
Triamterene—Dizziness—Topotecan—lung cancer	0.00148	0.0032	CcSEcCtD
Triamterene—Vomiting—Vinblastine—lung cancer	0.00147	0.00317	CcSEcCtD
Triamterene—Dizziness—Erlotinib—lung cancer	0.00147	0.00317	CcSEcCtD
Triamterene—CYP1A2—Estrogen metabolism—GSTA1—lung cancer	0.00147	0.0115	CbGpPWpGaD
Triamterene—Headache—Vinblastine—lung cancer	0.00145	0.00312	CcSEcCtD
Triamterene—Anaphylactic shock—Cisplatin—lung cancer	0.00144	0.0031	CcSEcCtD
Triamterene—Vomiting—Topotecan—lung cancer	0.00143	0.00308	CcSEcCtD
Triamterene—Rash—Topotecan—lung cancer	0.00141	0.00305	CcSEcCtD
Triamterene—Hypersensitivity—Vinorelbine—lung cancer	0.00141	0.00305	CcSEcCtD
Triamterene—Dermatitis—Topotecan—lung cancer	0.00141	0.00305	CcSEcCtD
Triamterene—Vomiting—Erlotinib—lung cancer	0.00141	0.00304	CcSEcCtD
Triamterene—Thrombocytopenia—Cisplatin—lung cancer	0.00141	0.00303	CcSEcCtD
Triamterene—Headache—Topotecan—lung cancer	0.00141	0.00303	CcSEcCtD
Triamterene—Rash—Erlotinib—lung cancer	0.0014	0.00302	CcSEcCtD
Triamterene—Dermatitis—Erlotinib—lung cancer	0.0014	0.00302	CcSEcCtD
Triamterene—SCNN1D—Transmembrane transport of small molecules—ABCC3—lung cancer	0.0014	0.011	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—ABCC3—lung cancer	0.0014	0.011	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—ABCC3—lung cancer	0.0014	0.011	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—ABCC3—lung cancer	0.0014	0.011	CbGpPWpGaD
Triamterene—Headache—Erlotinib—lung cancer	0.00139	0.003	CcSEcCtD
Triamterene—Asthenia—Vinorelbine—lung cancer	0.00138	0.00297	CcSEcCtD
Triamterene—Nausea—Vinblastine—lung cancer	0.00137	0.00296	CcSEcCtD
Triamterene—Fatigue—Irinotecan—lung cancer	0.00136	0.00294	CcSEcCtD
Triamterene—CYP1A2—Estrogen metabolism—UGT1A1—lung cancer	0.00136	0.0107	CbGpPWpGaD
Triamterene—Nausea—Topotecan—lung cancer	0.00133	0.00287	CcSEcCtD
Triamterene—Fatigue—Gemcitabine—lung cancer	0.00133	0.00287	CcSEcCtD
Triamterene—Nausea—Erlotinib—lung cancer	0.00132	0.00284	CcSEcCtD
Triamterene—Dry mouth—Paclitaxel—lung cancer	0.00132	0.00284	CcSEcCtD
Triamterene—Anaphylactic shock—Etoposide—lung cancer	0.00132	0.00284	CcSEcCtD
Triamterene—Diarrhoea—Vinorelbine—lung cancer	0.00131	0.00283	CcSEcCtD
Triamterene—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—lung cancer	0.0013	0.0102	CbGpPWpGaD
Triamterene—Anaphylactic shock—Paclitaxel—lung cancer	0.00129	0.00278	CcSEcCtD
Triamterene—Thrombocytopenia—Etoposide—lung cancer	0.00129	0.00278	CcSEcCtD
Triamterene—Dizziness—Vinorelbine—lung cancer	0.00127	0.00274	CcSEcCtD
Triamterene—SCNN1A—Transmembrane transport of small molecules—GNG11—lung cancer	0.00127	0.00998	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—GNG11—lung cancer	0.00127	0.00998	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—GNG11—lung cancer	0.00127	0.00998	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—GNG11—lung cancer	0.00127	0.00998	CbGpPWpGaD
Triamterene—Photosensitivity reaction—Methotrexate—lung cancer	0.00127	0.00273	CcSEcCtD
Triamterene—Hypokalaemia—Doxorubicin—lung cancer	0.00126	0.00273	CcSEcCtD
Triamterene—Thrombocytopenia—Paclitaxel—lung cancer	0.00126	0.00273	CcSEcCtD
Triamterene—CYP1A2—Fatty Acid Omega Oxidation—CYP2A6—lung cancer	0.00122	0.00962	CbGpPWpGaD
Triamterene—Vomiting—Vinorelbine—lung cancer	0.00122	0.00263	CcSEcCtD
Triamterene—Rash—Vinorelbine—lung cancer	0.00121	0.00261	CcSEcCtD
Triamterene—Dermatitis—Vinorelbine—lung cancer	0.00121	0.00261	CcSEcCtD
Triamterene—Headache—Vinorelbine—lung cancer	0.0012	0.00259	CcSEcCtD
Triamterene—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—lung cancer	0.00118	0.00931	CbGpPWpGaD
Triamterene—Hypersensitivity—Irinotecan—lung cancer	0.00117	0.00252	CcSEcCtD
Triamterene—SCNN1G—Ion channel transport—RAF1—lung cancer	0.00116	0.00911	CbGpPWpGaD
Triamterene—SCNN1A—Ion channel transport—RAF1—lung cancer	0.00116	0.00911	CbGpPWpGaD
Triamterene—SCNN1D—Ion channel transport—RAF1—lung cancer	0.00116	0.00911	CbGpPWpGaD
Triamterene—SCNN1B—Ion channel transport—RAF1—lung cancer	0.00116	0.00911	CbGpPWpGaD
Triamterene—CYP1A2—Tryptophan metabolism—HSD17B10—lung cancer	0.00114	0.009	CbGpPWpGaD
Triamterene—Nausea—Vinorelbine—lung cancer	0.00114	0.00246	CcSEcCtD
Triamterene—SCNN1B—Transmembrane transport of small molecules—ABCG2—lung cancer	0.00114	0.00898	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—ADCY1—lung cancer	0.00114	0.00898	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—ABCG2—lung cancer	0.00114	0.00898	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—ADCY1—lung cancer	0.00114	0.00898	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—ADCY1—lung cancer	0.00114	0.00898	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—ABCG2—lung cancer	0.00114	0.00898	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—ABCG2—lung cancer	0.00114	0.00898	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—ADCY1—lung cancer	0.00114	0.00898	CbGpPWpGaD
Triamterene—Asthenia—Irinotecan—lung cancer	0.00114	0.00245	CcSEcCtD
Triamterene—Fatigue—Etoposide—lung cancer	0.00114	0.00245	CcSEcCtD
Triamterene—Dry mouth—Docetaxel—lung cancer	0.00112	0.00241	CcSEcCtD
Triamterene—Fatigue—Paclitaxel—lung cancer	0.00111	0.0024	CcSEcCtD
Triamterene—Asthenia—Gemcitabine—lung cancer	0.00111	0.00239	CcSEcCtD
Triamterene—Photosensitivity reaction—Doxorubicin—lung cancer	0.0011	0.00236	CcSEcCtD
Triamterene—Anaphylactic shock—Docetaxel—lung cancer	0.00109	0.00236	CcSEcCtD
Triamterene—Diarrhoea—Irinotecan—lung cancer	0.00108	0.00234	CcSEcCtD
Triamterene—Thrombocytopenia—Docetaxel—lung cancer	0.00107	0.00231	CcSEcCtD
Triamterene—SCNN1G—Transmembrane transport of small molecules—TF—lung cancer	0.00106	0.00835	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—TF—lung cancer	0.00106	0.00835	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—TF—lung cancer	0.00106	0.00835	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—TF—lung cancer	0.00106	0.00835	CbGpPWpGaD
Triamterene—Hypersensitivity—Cisplatin—lung cancer	0.00106	0.00228	CcSEcCtD
Triamterene—Diarrhoea—Gemcitabine—lung cancer	0.00105	0.00228	CcSEcCtD
Triamterene—Dizziness—Irinotecan—lung cancer	0.00105	0.00226	CcSEcCtD
Triamterene—Jaundice—Doxorubicin—lung cancer	0.00104	0.00225	CcSEcCtD
Triamterene—CYP1A2—Fatty Acid Omega Oxidation—CYP2E1—lung cancer	0.00104	0.00818	CbGpPWpGaD
Triamterene—Asthenia—Cisplatin—lung cancer	0.00103	0.00222	CcSEcCtD
Triamterene—CYP1A2—Xenobiotics—CYP2A6—lung cancer	0.00102	0.00804	CbGpPWpGaD
Triamterene—Vomiting—Irinotecan—lung cancer	0.00101	0.00217	CcSEcCtD
Triamterene—Rash—Irinotecan—lung cancer	0.000998	0.00215	CcSEcCtD
Triamterene—Dermatitis—Irinotecan—lung cancer	0.000997	0.00215	CcSEcCtD
Triamterene—Headache—Irinotecan—lung cancer	0.000992	0.00214	CcSEcCtD
Triamterene—Diarrhoea—Cisplatin—lung cancer	0.000983	0.00212	CcSEcCtD
Triamterene—CYP1A2—Tamoxifen metabolism—CYP2A6—lung cancer	0.000982	0.00774	CbGpPWpGaD
Triamterene—Vomiting—Gemcitabine—lung cancer	0.00098	0.00211	CcSEcCtD
Triamterene—Rash—Gemcitabine—lung cancer	0.000972	0.0021	CcSEcCtD
Triamterene—Dermatitis—Gemcitabine—lung cancer	0.000971	0.00209	CcSEcCtD
Triamterene—Hypersensitivity—Etoposide—lung cancer	0.00097	0.00209	CcSEcCtD
Triamterene—Headache—Gemcitabine—lung cancer	0.000966	0.00208	CcSEcCtD
Triamterene—Hypersensitivity—Paclitaxel—lung cancer	0.000951	0.00205	CcSEcCtD
Triamterene—Asthenia—Etoposide—lung cancer	0.000945	0.00204	CcSEcCtD
Triamterene—Fatigue—Docetaxel—lung cancer	0.000943	0.00203	CcSEcCtD
Triamterene—Nausea—Irinotecan—lung cancer	0.00094	0.00203	CcSEcCtD
Triamterene—CYP1A2—Estrogen metabolism—NQO1—lung cancer	0.000934	0.00736	CbGpPWpGaD
Triamterene—Asthenia—Paclitaxel—lung cancer	0.000926	0.002	CcSEcCtD
Triamterene—Nausea—Gemcitabine—lung cancer	0.000916	0.00198	CcSEcCtD
Triamterene—Vomiting—Cisplatin—lung cancer	0.000914	0.00197	CcSEcCtD
Triamterene—Rash—Cisplatin—lung cancer	0.000906	0.00195	CcSEcCtD
Triamterene—Dermatitis—Cisplatin—lung cancer	0.000905	0.00195	CcSEcCtD
Triamterene—Diarrhoea—Etoposide—lung cancer	0.000901	0.00194	CcSEcCtD
Triamterene—Diarrhoea—Paclitaxel—lung cancer	0.000883	0.0019	CcSEcCtD
Triamterene—CYP1A2—Estrogen Receptor Pathway—CYP1A1—lung cancer	0.00088	0.00694	CbGpPWpGaD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—lung cancer	0.000871	0.00687	CbGpPWpGaD
Triamterene—Dizziness—Etoposide—lung cancer	0.000871	0.00188	CcSEcCtD
Triamterene—CYP1A2—Xenobiotics—CYP2E1—lung cancer	0.000868	0.00684	CbGpPWpGaD
Triamterene—Dizziness—Paclitaxel—lung cancer	0.000854	0.00184	CcSEcCtD
Triamterene—Nausea—Cisplatin—lung cancer	0.000854	0.00184	CcSEcCtD
Triamterene—Vomiting—Etoposide—lung cancer	0.000837	0.00181	CcSEcCtD
Triamterene—CYP1A2—Tamoxifen metabolism—CYP2E1—lung cancer	0.000835	0.00658	CbGpPWpGaD
Triamterene—Rash—Etoposide—lung cancer	0.00083	0.00179	CcSEcCtD
Triamterene—Dermatitis—Etoposide—lung cancer	0.000829	0.00179	CcSEcCtD
Triamterene—Headache—Etoposide—lung cancer	0.000825	0.00178	CcSEcCtD
Triamterene—Vomiting—Paclitaxel—lung cancer	0.000821	0.00177	CcSEcCtD
Triamterene—Rash—Paclitaxel—lung cancer	0.000814	0.00176	CcSEcCtD
Triamterene—Dermatitis—Paclitaxel—lung cancer	0.000813	0.00175	CcSEcCtD
Triamterene—Headache—Paclitaxel—lung cancer	0.000809	0.00174	CcSEcCtD
Triamterene—Hypersensitivity—Docetaxel—lung cancer	0.000806	0.00174	CcSEcCtD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—lung cancer	0.000797	0.00628	CbGpPWpGaD
Triamterene—Anaphylactic shock—Methotrexate—lung cancer	0.000789	0.0017	CcSEcCtD
Triamterene—Asthenia—Docetaxel—lung cancer	0.000785	0.00169	CcSEcCtD
Triamterene—Nausea—Etoposide—lung cancer	0.000782	0.00169	CcSEcCtD
Triamterene—Thrombocytopenia—Methotrexate—lung cancer	0.000772	0.00167	CcSEcCtD
Triamterene—Nausea—Paclitaxel—lung cancer	0.000767	0.00165	CcSEcCtD
Triamterene—Diarrhoea—Docetaxel—lung cancer	0.000749	0.00161	CcSEcCtD
Triamterene—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—lung cancer	0.000746	0.00587	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—AVP—lung cancer	0.000734	0.00578	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—AVP—lung cancer	0.000734	0.00578	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—AVP—lung cancer	0.000734	0.00578	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—AVP—lung cancer	0.000734	0.00578	CbGpPWpGaD
Triamterene—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—lung cancer	0.00073	0.00575	CbGpPWpGaD
Triamterene—Dizziness—Docetaxel—lung cancer	0.000724	0.00156	CcSEcCtD
Triamterene—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—lung cancer	0.00072	0.00568	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—GSTA2—lung cancer	0.000717	0.00565	CbGpPWpGaD
Triamterene—CYP1A2—Estrogen metabolism—GSTM1—lung cancer	0.000716	0.00564	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000711	0.0056	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000711	0.0056	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000711	0.0056	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000711	0.0056	CbGpPWpGaD
Triamterene—Dry mouth—Doxorubicin—lung cancer	0.000697	0.0015	CcSEcCtD
Triamterene—Vomiting—Docetaxel—lung cancer	0.000696	0.0015	CcSEcCtD
Triamterene—Rash—Docetaxel—lung cancer	0.00069	0.00149	CcSEcCtD
Triamterene—Dermatitis—Docetaxel—lung cancer	0.000689	0.00149	CcSEcCtD
Triamterene—Headache—Docetaxel—lung cancer	0.000685	0.00148	CcSEcCtD
Triamterene—Anaphylactic shock—Doxorubicin—lung cancer	0.000683	0.00147	CcSEcCtD
Triamterene—Fatigue—Methotrexate—lung cancer	0.00068	0.00147	CcSEcCtD
Triamterene—CYP1A2—Estrogen metabolism—CYP1A1—lung cancer	0.000679	0.00535	CbGpPWpGaD
Triamterene—Thrombocytopenia—Doxorubicin—lung cancer	0.000669	0.00144	CcSEcCtD
Triamterene—Nausea—Docetaxel—lung cancer	0.00065	0.0014	CcSEcCtD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—UGT1A1—lung cancer	0.000643	0.00507	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—AHR—lung cancer	0.000626	0.00493	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—AHR—lung cancer	0.000626	0.00493	CbGpPWpGaD
Triamterene—CYP1A2—Xenobiotics—CYP1A1—lung cancer	0.000624	0.00491	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—lung cancer	0.00061	0.0048	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—lung cancer	0.00061	0.0048	CbGpPWpGaD
Triamterene—CYP1A2—Tamoxifen metabolism—CYP1A1—lung cancer	0.0006	0.00473	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTM2—lung cancer	0.000594	0.00468	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—CNDP2—lung cancer	0.000594	0.00468	CbGpPWpGaD
Triamterene—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—lung cancer	0.000592	0.00466	CbGpPWpGaD
Triamterene—Fatigue—Doxorubicin—lung cancer	0.000589	0.00127	CcSEcCtD
Triamterene—Hypersensitivity—Methotrexate—lung cancer	0.000581	0.00125	CcSEcCtD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—lung cancer	0.000568	0.00447	CbGpPWpGaD
Triamterene—Asthenia—Methotrexate—lung cancer	0.000566	0.00122	CcSEcCtD
Triamterene—SCNN1G—Transmembrane transport of small molecules—APOA1—lung cancer	0.000561	0.00442	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—APOA1—lung cancer	0.000561	0.00442	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—APOA1—lung cancer	0.000561	0.00442	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—APOA1—lung cancer	0.000561	0.00442	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—lung cancer	0.000547	0.00431	CbGpPWpGaD
Triamterene—Diarrhoea—Methotrexate—lung cancer	0.00054	0.00116	CcSEcCtD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—lung cancer	0.000524	0.00413	CbGpPWpGaD
Triamterene—Dizziness—Methotrexate—lung cancer	0.000521	0.00112	CcSEcCtD
Triamterene—CYP1A2—Arachidonic acid metabolism—HPGDS—lung cancer	0.000512	0.00403	CbGpPWpGaD
Triamterene—Hypersensitivity—Doxorubicin—lung cancer	0.000503	0.00109	CcSEcCtD
Triamterene—Vomiting—Methotrexate—lung cancer	0.000501	0.00108	CcSEcCtD
Triamterene—Rash—Methotrexate—lung cancer	0.000497	0.00107	CcSEcCtD
Triamterene—Dermatitis—Methotrexate—lung cancer	0.000497	0.00107	CcSEcCtD
Triamterene—Headache—Methotrexate—lung cancer	0.000494	0.00107	CcSEcCtD
Triamterene—Asthenia—Doxorubicin—lung cancer	0.00049	0.00106	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—GSTA3—lung cancer	0.000479	0.00377	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000475	0.00374	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000475	0.00374	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000475	0.00374	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000475	0.00374	CbGpPWpGaD
Triamterene—CYP1A2—Estrogen Receptor Pathway—JUN—lung cancer	0.000472	0.00372	CbGpPWpGaD
Triamterene—Nausea—Methotrexate—lung cancer	0.000468	0.00101	CcSEcCtD
Triamterene—Diarrhoea—Doxorubicin—lung cancer	0.000467	0.00101	CcSEcCtD
Triamterene—CYP1A2—Melatonin metabolism and effects—CYP1A1—lung cancer	0.000463	0.00365	CbGpPWpGaD
Triamterene—Dizziness—Doxorubicin—lung cancer	0.000452	0.000974	CcSEcCtD
Triamterene—CYP1A2—Tryptophan metabolism—CYP2E1—lung cancer	0.000446	0.00351	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—ALB—lung cancer	0.000445	0.0035	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—ALB—lung cancer	0.000445	0.0035	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—ALB—lung cancer	0.000445	0.0035	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—ALB—lung cancer	0.000445	0.0035	CbGpPWpGaD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—lung cancer	0.000443	0.00349	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—lung cancer	0.000441	0.00347	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—lung cancer	0.000441	0.00347	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTA4—lung cancer	0.000438	0.00345	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUNB—lung cancer	0.000438	0.00345	CbGpPWpGaD
Triamterene—Vomiting—Doxorubicin—lung cancer	0.000434	0.000936	CcSEcCtD
Triamterene—Rash—Doxorubicin—lung cancer	0.000431	0.000929	CcSEcCtD
Triamterene—Dermatitis—Doxorubicin—lung cancer	0.00043	0.000928	CcSEcCtD
Triamterene—Headache—Doxorubicin—lung cancer	0.000428	0.000923	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—GSTA2—lung cancer	0.000427	0.00336	CbGpPWpGaD
Triamterene—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—lung cancer	0.000424	0.00334	CbGpPWpGaD
Triamterene—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—lung cancer	0.000418	0.0033	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTA1—lung cancer	0.000412	0.00324	CbGpPWpGaD
Triamterene—CYP1A2—Estrogen Receptor Pathway—STAT3—lung cancer	0.000408	0.00322	CbGpPWpGaD
Triamterene—Nausea—Doxorubicin—lung cancer	0.000406	0.000875	CcSEcCtD
Triamterene—SCNN1B—Transmembrane transport of small molecules—RAF1—lung cancer	0.000402	0.00317	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—RAF1—lung cancer	0.000402	0.00317	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—RAF1—lung cancer	0.000402	0.00317	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—RAF1—lung cancer	0.000402	0.00317	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—UGT1A1—lung cancer	0.000383	0.00302	CbGpPWpGaD
Triamterene—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2E1—lung cancer	0.000361	0.00284	CbGpPWpGaD
Triamterene—CYP1A2—Tryptophan metabolism—CAT—lung cancer	0.000358	0.00282	CbGpPWpGaD
Triamterene—CYP1A2—Oxidation by Cytochrome P450—CYP2E1—lung cancer	0.000356	0.0028	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—CNDP2—lung cancer	0.000348	0.00274	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTM2—lung cancer	0.000348	0.00274	CbGpPWpGaD
Triamterene—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—lung cancer	0.000344	0.00271	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTM2—lung cancer	0.000343	0.0027	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—lung cancer	0.00034	0.00268	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—HPGDS—lung cancer	0.000326	0.00256	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—lung cancer	0.00032	0.00252	CbGpPWpGaD
Triamterene—CYP1A2—Tryptophan metabolism—CYP1A1—lung cancer	0.00032	0.00252	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—lung cancer	0.00032	0.00252	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTT1—lung cancer	0.000316	0.00249	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—CYP2A7—lung cancer	0.000314	0.00248	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GCLC—lung cancer	0.000312	0.00246	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—CYP2A7—lung cancer	0.00031	0.00244	CbGpPWpGaD
Triamterene—CYP1A2—Arachidonic acid metabolism—CYP1A1—lung cancer	0.0003	0.00236	CbGpPWpGaD
Triamterene—CYP1A2—Phase 1 - Functionalization of compounds—CYP2E1—lung cancer	0.000292	0.0023	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTA3—lung cancer	0.00028	0.00221	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTA3—lung cancer	0.000276	0.00218	CbGpPWpGaD
Triamterene—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	0.000259	0.00204	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTA4—lung cancer	0.000256	0.00202	CbGpPWpGaD
Triamterene—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—lung cancer	0.000256	0.00201	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTA4—lung cancer	0.000253	0.00199	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTA2—lung cancer	0.00025	0.00197	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTA1—lung cancer	0.000241	0.0019	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—RB1—lung cancer	0.000232	0.00183	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—AKR1C1—lung cancer	0.000228	0.00179	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—UGT1A1—lung cancer	0.000224	0.00176	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—MAP2K1—lung cancer	0.000222	0.00175	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—UGT1A1—lung cancer	0.000221	0.00174	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—COL4A3BP—lung cancer	0.00022	0.00174	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTP1—lung cancer	0.000219	0.00172	CbGpPWpGaD
Triamterene—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	0.00021	0.00165	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTM1—lung cancer	0.000201	0.00158	CbGpPWpGaD
Triamterene—CYP1A2—Tryptophan metabolism—MDM2—lung cancer	0.000198	0.00156	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—lung cancer	0.000197	0.00155	CbGpPWpGaD
Triamterene—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	0.000193	0.00152	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—lung cancer	0.000191	0.0015	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—HPGDS—lung cancer	0.00019	0.0015	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTT1—lung cancer	0.000185	0.00146	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—CYP2A6—lung cancer	0.000183	0.00144	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GCLC—lung cancer	0.000183	0.00144	CbGpPWpGaD
Triamterene—CYP1A2—Arachidonic acid metabolism—PTGS2—lung cancer	0.000178	0.0014	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—lung cancer	0.000177	0.00139	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—lung cancer	0.000172	0.00135	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PLBD1—lung cancer	0.000167	0.00132	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—lung cancer	0.000167	0.00131	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—lung cancer	0.000158	0.00125	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—EP300—lung cancer	0.000158	0.00125	CbGpPWpGaD
Triamterene—CYP1A2—Phase 1 - Functionalization of compounds—POMC—lung cancer	0.000157	0.00123	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—CYP2E1—lung cancer	0.000155	0.00122	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—lung cancer	0.000154	0.00121	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—SRC—lung cancer	0.000154	0.00121	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—CYP2E1—lung cancer	0.000153	0.00121	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—lung cancer	0.00015	0.00118	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—lung cancer	0.000148	0.00117	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—MYC—lung cancer	0.000138	0.00109	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—lung cancer	0.000135	0.00106	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—lung cancer	0.000135	0.00106	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—lung cancer	0.00013	0.00102	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTP1—lung cancer	0.000128	0.00101	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—lung cancer	0.000128	0.00101	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTP1—lung cancer	0.000126	0.000995	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTM1—lung cancer	0.000118	0.000927	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTM1—lung cancer	0.000116	0.000914	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—CYP1A1—lung cancer	0.000112	0.000879	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—CYP1A1—lung cancer	0.00011	0.000867	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—lung cancer	0.000108	0.000854	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—COL4A3BP—lung cancer	9.81e-05	0.000773	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—AZIN2—lung cancer	9.81e-05	0.000773	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	9.15e-05	0.000721	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	8.86e-05	0.000698	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ATP5H—lung cancer	8.34e-05	0.000657	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—POMC—lung cancer	8.32e-05	0.000655	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	7.67e-05	0.000604	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PLBD1—lung cancer	7.44e-05	0.000586	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	7.31e-05	0.000576	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—HSD17B10—lung cancer	6.8e-05	0.000536	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CKB—lung cancer	6.32e-05	0.000498	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTM2—lung cancer	5.94e-05	0.000468	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CNDP2—lung cancer	5.94e-05	0.000468	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—MTMR3—lung cancer	5.78e-05	0.000456	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PGAM1—lung cancer	5.63e-05	0.000444	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CYP2A7—lung cancer	5.38e-05	0.000424	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—SDC4—lung cancer	5.26e-05	0.000414	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTA3—lung cancer	4.79e-05	0.000377	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—RRM1—lung cancer	4.79e-05	0.000377	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—B4GALT5—lung cancer	4.5e-05	0.000355	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTA4—lung cancer	4.38e-05	0.000345	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	4.28e-05	0.000337	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTA2—lung cancer	4.27e-05	0.000336	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTA1—lung cancer	4.12e-05	0.000325	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ABCC3—lung cancer	4.07e-05	0.000321	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—AKR1C1—lung cancer	3.95e-05	0.000311	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—UGT1A1—lung cancer	3.83e-05	0.000302	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GNG11—lung cancer	3.69e-05	0.000291	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	3.67e-05	0.00029	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ALDOA—lung cancer	3.52e-05	0.000277	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—NCOA3—lung cancer	3.41e-05	0.000269	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	3.35e-05	0.000264	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ADCY1—lung cancer	3.32e-05	0.000262	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ABCG2—lung cancer	3.32e-05	0.000262	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—HPGDS—lung cancer	3.26e-05	0.000257	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ENO2—lung cancer	3.26e-05	0.000257	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PPP2R1B—lung cancer	3.24e-05	0.000255	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	3.19e-05	0.000252	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTT1—lung cancer	3.16e-05	0.000249	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CYP2A6—lung cancer	3.12e-05	0.000246	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GCLC—lung cancer	3.12e-05	0.000246	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.11e-05	0.000245	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ENO1—lung cancer	2.96e-05	0.000233	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	2.95e-05	0.000232	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	2.91e-05	0.000229	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CYP2E1—lung cancer	2.65e-05	0.000209	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—NQO1—lung cancer	2.63e-05	0.000207	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.57e-05	0.000203	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.55e-05	0.000201	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—STK11—lung cancer	2.37e-05	0.000186	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.22e-05	0.000175	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTP1—lung cancer	2.19e-05	0.000173	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CAT—lung cancer	2.13e-05	0.000168	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.12e-05	0.000167	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ABCB1—lung cancer	2.07e-05	0.000163	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—TYMS—lung cancer	2.04e-05	0.00016	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTM1—lung cancer	2.01e-05	0.000159	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CYP1A1—lung cancer	1.91e-05	0.00015	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ERCC2—lung cancer	1.89e-05	0.000149	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—APOA1—lung cancer	1.64e-05	0.000129	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.57e-05	0.000123	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PIK3CG—lung cancer	1.49e-05	0.000118	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—POMC—lung cancer	1.42e-05	0.000112	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CREBBP—lung cancer	1.39e-05	0.000109	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PIK3CD—lung cancer	1.31e-05	0.000103	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ALB—lung cancer	1.3e-05	0.000102	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PIK3CB—lung cancer	1.14e-05	9.02e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PTGS2—lung cancer	1.13e-05	8.94e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PTEN—lung cancer	9.89e-06	7.79e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—EP300—lung cancer	9.43e-06	7.43e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PIK3CA—lung cancer	6.98e-06	5.5e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—AKT1—lung cancer	5.7e-06	4.49e-05	CbGpPWpGaD
